title: Epigallocatechin-3-gallate inhibits proliferation and migration of human colon cancer SW620 cells in vitro.
abstract: OBJECTIVE
  Epigallocatechin-3-gallate (EGCG) is the major polyphenolic constituent in green tea. The aim of this study is to investigate the effects of EGCG on proliferation and migration of the human colon cancer SW620 cells.
  
  
  METHODS
  Proliferation and migration of SW620 cells were induced by the protease-activated receptor 2-agonist peptide (PAR2-AP, 100 μmol/L) or factor VIIa (10 nmol/L), and analyzed using MTT and Transwell assays, respectively. The cellular cytoskeleton was stained with rhodamine-conjugated phalloidin and examined with a laser scanning confocal fluorescence microscope. The expression of caspase-7, tissue factor (TF) and matrix metalloproteinase (MMP)-9 in the cells was examined using QT-PCR, ELISA and Western blot assays. The activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and nuclear factor-kappa B (NF-κB) signaling pathways was analyzed with Western blot.
  
  
  RESULTS
  Both PAR2-AP and factor VIIa promoted SW620 cell proliferation and migration, and caused cytoskeleton reorganization (increased filopodia and pseudopodia). Pretreatment with EGCG (25, 50, 75, and 100 μg/mL) dose-dependently blocked the cell proliferation and migration induced by PAR2-AP or factor VIIa. EGCG (100 μg/mL) prevented the cytoskeleton changes induced by PAR2-AP or factor VIIa. EGCG (100 μg/mL) counteracted the down-regulation of caspase-7 expression and up-regulation of TF and MMP-9 expression in the cells treated with PAR2-AP or factor VIIa. Furthermore, it blocked the activation of ERK1/2 and NF-κB (p65/RelA) induced by PAR2-AP or factor VIIa.
  
  
  CONCLUSIONS
  EGCG blocks the proliferation and migration of SW620 cells induced by PAR2-AP and factor VIIa via inhibition of the ERK1/2 and NF-κB pathways. The compound may serve as a preventive and therapeutic agent for colon cancers.
authors.affiliation: Department of Clinical Laboratory, Jiangsu Province Rongjun Hospital, Wuxi, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Zhou
authors.forename: Hong
authors.initials: H
authors.lastname: Zhou
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Mu
authors.forename: Biao
authors.initials: B
authors.lastname: Wu
authors.forename: Dong-lin
authors.initials: DL
authors.lastname: Guo
authors.forename: Xian-mei
authors.initials: XM
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: Wu
mesh_terms: D016588:Anticarcinogenic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D053179:Caspase 7 / Q000378:metabolism; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D003599:Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D015942:Factor VIIa / Q000494:pharmacology; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D044464:Receptor, PAR-2 / Q000819:agonists; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: C487404:2-furoyl-LIGRLO-amide; D016588:Anticarcinogenic Agents; D016328:NF-kappa B; D009842:Oligopeptides; D044464:Receptor, PAR-2; D002392:Catechin; C045651:epigallocatechin gallate; D048049:Extracellular Signal-Regulated MAP Kinases; D015942:Factor VIIa; D053179:Caspase 7; D020780:Matrix Metalloproteinase 9
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12815-9
references.pmid: 18723680
references.citation: Cancer Res. 2006 Jan 1;66(1):307-14
references.pmid: 16397244
references.citation: Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1447-55
references.pmid: 17413039
references.citation: Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1545-50
references.pmid: 15905465
references.citation: Acta Crystallogr D Biol Crystallogr. 2007 Jun;63(Pt 6):689-97
references.pmid: 17505107
references.citation: Blood. 2008 Jan 1;111(1):190-9
references.pmid: 17901245
references.citation: Biochim Biophys Acta. 2007 May;1773(5):675-86
references.pmid: 17050008
references.citation: Acta Pharmacol Sin. 2011 Jan;32(1):52-61
references.pmid: 21151160
references.citation: Oncogene. 2004 Apr 1;23(14):2507-22
references.pmid: 14676829
references.citation: Oncol Rep. 2011 Feb;25(2):503-11
references.pmid: 21152870
references.citation: Clin Cancer Res. 2007 May 15;13(10):2870-5
references.pmid: 17504985
references.citation: Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G335-46
references.pmid: 17431214
references.citation: Tumour Biol. 2011 Oct;32(5):921-30
references.pmid: 21625939
references.citation: FEBS Lett. 2009 Sep 3;583(17):2811-8
references.pmid: 19631649
references.citation: Cell Mol Immunol. 2009 Oct;6(5):327-34
references.pmid: 19887045
references.citation: Cancer Lett. 2008 Nov 18;271(1):140-52
references.pmid: 18632202
references.citation: Oncol Rep. 2008 Nov;20(5):1069-76
references.pmid: 18949403
references.citation: Best Pract Res Clin Haematol. 2009 Mar;22(1):71-83
references.pmid: 19285274
references.citation: Toxicol In Vitro. 2009 Aug;23(5):834-9
references.pmid: 19406223
references.citation: Leuk Res. 2007 Sep;31(9):1277-84
references.pmid: 17081606
references.citation: Acta Pharmacol Sin. 2009 Apr;30(4):435-41
references.pmid: 19305422
references.citation: J Thromb Haemost. 2007 Aug;5(8):1588-97
references.pmid: 17470200
references.citation: Cell Death Differ. 2009 Mar;16(3):368-77
references.pmid: 18846109
references.citation: J Surg Res. 2009 May 15;153(2):239-45
references.pmid: 19062044
references.citation: Mol Med Rep. 2010 Mar-Apr;3(2):269-74
references.pmid: 21472232
references.citation: Cancer Lett. 2008 Oct 8;269(2):269-80
references.pmid: 18501505
references.citation: Nat Rev Cancer. 2009 Jun;9(6):429-39
references.pmid: 19472429
references.citation: Thromb Res. 2008;122 Suppl 1:S11-3
references.pmid: 18691491